Victory Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Victory Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-17,605	Closed	-$43K	–	2812
2020 Q4	$43K	Sell	17,605 -202,912	-92%	-$494K	﹤0.01%	2467
2020 Q3	$695K	Buy	220,517 +13,937	+7%	+$44.5K	﹤0.01%	1847
2020 Q2	$601K	Sell	206,580 -170,652	-45%	-$540K	﹤0.01%	1931
2020 Q1	$1.06M	Buy	377,232 +227,043	+151%	+$732K	﹤0.01%	1828
2019 Q4	$487K	Buy	150,189 +63,653	+74%	+$185K	﹤0.01%	2024
2019 Q3	$187K	Buy	+86,536	New	+$231K	﹤0.01%	2241
2016 Q1	–	Sell	-60,949	Closed	-$216K	–	1824
2015 Q4	$216K	Buy	60,949 +21,516	+55%	+$90.1K	﹤0.01%	1157
2015 Q3	$198K	Buy	39,433 +16,837	+75%	+$96.5K	﹤0.01%	1119
2015 Q2	$145K	Buy	+22,596	New	+$151K	﹤0.01%	1150

Other funds holding PDLI

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Public Employees Retirement Association of Colorado Denver, Colorado $25.5B AUM 28.85% 1-Year Est. Return

Victory Capital Management's PDLI Position: Q1 2021 in Review

Victory Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q1 2021, closing a stake of 17,605 shares — an estimated $43K sold.

Victory Capital Management first reported a position in PDLI in Q2 2015 and held it in 9 quarters. The position peaked at $1.06M in Q1 2020. 11 funds tracked by Wall St. Rank hold PDLI as of Q1 2021.

Victory Capital Management reported no remaining PDL BioPharma, Inc. position as of Q1 2021 after selling out during the quarter.
Victory Capital Management sold 17,605 PDL BioPharma, Inc. shares in Q1 2021, an estimated $43K.
Victory Capital Management first reported a position in PDL BioPharma, Inc. in Q2 2015 and held it in 9 quarters.
Victory Capital Management's PDL BioPharma, Inc. position peaked at $1.06M in Q1 2020.
11 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2021.

Based on Victory Capital Management's 13F filing for Q1 2021, filed 4 May 2021.